Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers
- PMID: 17192771
- DOI: 10.1038/sj.clpt.6100037
Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers
Abstract
1,4-Butanediol (BD) is converted to gamma-hydroxybutyrate (GHB) after ingestion, and is associated with cases of dependence, coma, and death. The pharmacology of BD after oral ingestion has not been described in humans. Eight healthy volunteers (five men) were administered 25 mg/kg BD in a single oral dose after an overnight fast in a double-blinded, placebo-controlled, crossover study. Vital signs were monitored, and serial blood samples collected over 24 h for gas chromatography-mass spectrometry analysis of BD and GHB levels. Subjective mood and symptoms responses were assessed by visual analog scale. All subjects completed the study without significant adverse effects. BD was quickly absorbed and cleared, with time to maximal plasma concentration of 24+/-12 min, and elimination half-life (T(1/2)) of 39.3+/-11 min. BD was extensively converted to GHB, with a mean maximum GHB concentration of 45.6+/-19.7 mg/l reached 39.4+/-11.2 min after BD ingestion. GHB T(1/2) averaged 32.3+/-6.6 min. Some subjects exhibited slow oral clearance of BD, which tended to correlate with a variant haplotype of the alcohol dehydrogenase gene ADH-IB G143A. Mean CL/F was 151.5+/-176.5 ml/min kg for four subjects with variant haplotype versus 598.8+/-446.6 ml/min kg for four wild-type subjects (P=0.061). Subjects reported feeling less awake and alert, less able to concentrate, and more lightheaded in the first 90 min after BD ingestion. Pulse oximetry readings were lower 45 min after BD dosing with a mean oxygen saturation of 98.5% with BD versus 99.6% with placebo (P=0.031). Transient increases in mean systolic and diastolic blood pressure were observed, but other vital signs remained unchanged. BD was extensively converted to GHB after oral administration, but significant inter-individual variability in the rate of metabolism, possibly related to variants in ADH-IB, was observed. At the modest dose studied, significant clinical effects were not seen.
Similar articles
-
The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients.J Clin Pharmacol. 2004 Mar;44(3):253-7. doi: 10.1177/0091270003262795. J Clin Pharmacol. 2004. PMID: 14973300 Clinical Trial.
-
Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.Clin Ther. 2007 Aug;29(8):1692-705. doi: 10.1016/j.clinthera.2007.08.005. Clin Ther. 2007. PMID: 17919550 Clinical Trial.
-
Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics.Ann N Y Acad Sci. 2006 Aug;1074:559-76. doi: 10.1196/annals.1369.065. Ann N Y Acad Sci. 2006. PMID: 17105953 Clinical Trial.
-
The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.Clin Toxicol (Phila). 2012 Jul;50(6):458-70. doi: 10.3109/15563650.2012.702218. Clin Toxicol (Phila). 2012. PMID: 22746383 Review.
-
Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use.Neurosci Biobehav Rev. 2015 Jun;53:52-78. doi: 10.1016/j.neubiorev.2015.03.012. Epub 2015 Apr 3. Neurosci Biobehav Rev. 2015. PMID: 25843781 Review.
Cited by
-
Effect of γ-hydroxybutyrate (GHB) on driving as measured by a driving simulator.Psychopharmacology (Berl). 2018 Nov;235(11):3223-3232. doi: 10.1007/s00213-018-5025-2. Epub 2018 Sep 19. Psychopharmacology (Berl). 2018. PMID: 30232528 Free PMC article. Clinical Trial.
-
Behavioral effects and pharmacokinetics of gamma-hydroxybutyrate (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons.Psychopharmacology (Berl). 2009 Jun;204(3):465-76. doi: 10.1007/s00213-009-1477-8. Epub 2009 Feb 6. Psychopharmacology (Berl). 2009. PMID: 19198808 Free PMC article.
-
Gamma-hydroxybutyrate abuse: pharmacology and poisoning and withdrawal management.Arh Hig Rada Toksikol. 2020 Mar 1;71(1):19-26. doi: 10.2478/aiht-2020-71-3314. Arh Hig Rada Toksikol. 2020. PMID: 32597141 Free PMC article. Review.
-
Structure-activity models of oral clearance, cytotoxicity, and LD50: a screen for promising anticancer compounds.BMC Pharmacol. 2008 Jun 13;8:12. doi: 10.1186/1471-2210-8-12. BMC Pharmacol. 2008. PMID: 18554402 Free PMC article.
-
Consequences of 1,4-Butanediol Misuse: A Review.Psychopharmacol Bull. 2023 Dec 4;53(4):48-53. Psychopharmacol Bull. 2023. PMID: 38076667 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical